Cargando…
FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial
PURPOSE: To evaluate cost-effectiveness of an [(18)F]FDG-PET/CT-driven diagnostic workup as compared to diagnostic surgery, for thyroid nodules with Bethesda III/IV cytology. [(18)F]FDG-PET/CT avoids 40% of futile diagnostic surgeries for benign Bethesda III/IV nodules. METHODS: Lifelong societal co...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308600/ https://www.ncbi.nlm.nih.gov/pubmed/35435497 http://dx.doi.org/10.1007/s00259-022-05794-w |
_version_ | 1784753016504582144 |
---|---|
author | de Koster, Elizabeth J. Vriens, Dennis van Aken, Maarten O. Dijkhorst-Oei, Lioe-Ting Oyen, Wim J. G. Peeters, Robin P. Schepers, Abbey de Geus-Oei, Lioe-Fee van den Hout, Wilbert B. |
author_facet | de Koster, Elizabeth J. Vriens, Dennis van Aken, Maarten O. Dijkhorst-Oei, Lioe-Ting Oyen, Wim J. G. Peeters, Robin P. Schepers, Abbey de Geus-Oei, Lioe-Fee van den Hout, Wilbert B. |
author_sort | de Koster, Elizabeth J. |
collection | PubMed |
description | PURPOSE: To evaluate cost-effectiveness of an [(18)F]FDG-PET/CT-driven diagnostic workup as compared to diagnostic surgery, for thyroid nodules with Bethesda III/IV cytology. [(18)F]FDG-PET/CT avoids 40% of futile diagnostic surgeries for benign Bethesda III/IV nodules. METHODS: Lifelong societal costs and quality-adjusted life years (QALYs) were assessed for 132 patients participating in a randomised controlled multicentre trial comparing [(18)F]FDG-PET/CT to diagnostic surgery. The observed 1-year trial results were extrapolated using a Markov model. The probability of cost-effectiveness was estimated using cost-effectiveness acceptability curves, taking uncertainty about sampling, imputation, and parameters into account. RESULTS: The observed 1-year cost difference of [(18)F]FDG-PET/CT as compared to diagnostic surgery was − €1000 (95% CI: − €2100 to €0) for thyroid nodule–related care (p = 0.06). From the broader societal perspective, the 1-year difference in total societal costs was − €4500 (− €9200 to €150) (p = 0.06). Over the modelled lifelong period, the cost difference was − €9900 (− €23,100 to €3200) (p = 0.14). The difference in QALYs was 0.019 (− 0.045 to 0.083) at 1 year (p = 0.57) and 0.402 (− 0.581 to 1.385) over the lifelong period (p = 0.42). For a willingness to pay of €50,000 per QALY, an [(18)F]FDG-PET/CT-driven work-up was the cost-effective strategy with 84% certainty. CONCLUSION: Following the observed reduction in diagnostic surgery, an [(18)F]FDG-PET/CT-driven diagnostic workup reduced the 1-year thyroid nodule–related and societal costs while sustaining quality of life. It is very likely cost-effective as compared to diagnostic surgery for Bethesda III/IV nodules. Trial registration number: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05794-w. |
format | Online Article Text |
id | pubmed-9308600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-93086002022-07-25 FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial de Koster, Elizabeth J. Vriens, Dennis van Aken, Maarten O. Dijkhorst-Oei, Lioe-Ting Oyen, Wim J. G. Peeters, Robin P. Schepers, Abbey de Geus-Oei, Lioe-Fee van den Hout, Wilbert B. Eur J Nucl Med Mol Imaging Original Article PURPOSE: To evaluate cost-effectiveness of an [(18)F]FDG-PET/CT-driven diagnostic workup as compared to diagnostic surgery, for thyroid nodules with Bethesda III/IV cytology. [(18)F]FDG-PET/CT avoids 40% of futile diagnostic surgeries for benign Bethesda III/IV nodules. METHODS: Lifelong societal costs and quality-adjusted life years (QALYs) were assessed for 132 patients participating in a randomised controlled multicentre trial comparing [(18)F]FDG-PET/CT to diagnostic surgery. The observed 1-year trial results were extrapolated using a Markov model. The probability of cost-effectiveness was estimated using cost-effectiveness acceptability curves, taking uncertainty about sampling, imputation, and parameters into account. RESULTS: The observed 1-year cost difference of [(18)F]FDG-PET/CT as compared to diagnostic surgery was − €1000 (95% CI: − €2100 to €0) for thyroid nodule–related care (p = 0.06). From the broader societal perspective, the 1-year difference in total societal costs was − €4500 (− €9200 to €150) (p = 0.06). Over the modelled lifelong period, the cost difference was − €9900 (− €23,100 to €3200) (p = 0.14). The difference in QALYs was 0.019 (− 0.045 to 0.083) at 1 year (p = 0.57) and 0.402 (− 0.581 to 1.385) over the lifelong period (p = 0.42). For a willingness to pay of €50,000 per QALY, an [(18)F]FDG-PET/CT-driven work-up was the cost-effective strategy with 84% certainty. CONCLUSION: Following the observed reduction in diagnostic surgery, an [(18)F]FDG-PET/CT-driven diagnostic workup reduced the 1-year thyroid nodule–related and societal costs while sustaining quality of life. It is very likely cost-effective as compared to diagnostic surgery for Bethesda III/IV nodules. Trial registration number: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05794-w. Springer Berlin Heidelberg 2022-04-18 2022 /pmc/articles/PMC9308600/ /pubmed/35435497 http://dx.doi.org/10.1007/s00259-022-05794-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article de Koster, Elizabeth J. Vriens, Dennis van Aken, Maarten O. Dijkhorst-Oei, Lioe-Ting Oyen, Wim J. G. Peeters, Robin P. Schepers, Abbey de Geus-Oei, Lioe-Fee van den Hout, Wilbert B. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
title | FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
title_full | FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
title_fullStr | FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
title_full_unstemmed | FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
title_short | FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
title_sort | fdg-pet/ct in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308600/ https://www.ncbi.nlm.nih.gov/pubmed/35435497 http://dx.doi.org/10.1007/s00259-022-05794-w |
work_keys_str_mv | AT dekosterelizabethj fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT vriensdennis fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT vanakenmaarteno fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT dijkhorstoeilioeting fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT oyenwimjg fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT peetersrobinp fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT schepersabbey fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT degeusoeilioefee fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT vandenhoutwilbertb fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial AT fdgpetctinindeterminatethyroidnodulescostutilityanalysisalongsidearandomisedcontrolledtrial |